Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.

Clinical genetics - 1 Jun 2007

Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, Angell J, Skrinar A, Pastores G M

Abstract excerpt

Health-related quality of life (HRQOL) can be diminished in patients with type 1 Gaucher disease (GD) owing to the debilitating clinical manifestations of this chronic disease. This study investigates the impact of imiglucerase treatment on HRQOL of patients with type 1 GD and bone involvement. Thirty-two previously untreated type 1 GD patients with skeletal manifestations including bone pain, medullary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Density
Share to Bone Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gaucher Disease

Share to Genotype

Share to Glucosylceramidase

Share to Quality of Life

Share to Surveys and Questionnaires

Share to Treatment Outcome

Source

Identifiers

PMID: 17539908
DOI: 10.1111/j.1399-0004.2007.00811.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.PMID 17539908Read ↗

Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Semantic proximity Read ↗

Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.Semantic proximity Read ↗

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.Semantic proximity Read ↗

A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.Semantic proximity Read ↗

Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.Semantic proximity Read ↗

A validated disease severity scoring system for adults with type 1 Gaucher disease.Semantic proximity Read ↗

Health-Related Quality of Life in Fabry Disease: A Cross-sectional International Multicenter StudySemantic proximity Read ↗

Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.Semantic proximity Read ↗

Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease.Semantic proximity Read ↗

Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease.Semantic proximity Read ↗

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.Semantic proximity Read ↗

Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.